Edition:
United States

Aquinox Pharmaceuticals Inc (AQXP.OQ)

AQXP.OQ on NASDAQ Stock Exchange Global Market

11.31USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$11.31
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
25,990
52-wk High
$19.90
52-wk Low
$10.03

Latest Key Developments (Source: Significant Developments)

Aquinox Pharmaceuticals qtrly ‍net loss per share $0.50​
Wednesday, 8 Nov 2017 09:05am EST 

Nov 8 (Reuters) - Aquinox Pharmaceuticals Inc -:Aquinox Pharmaceuticals announces third quarter 2017 financial results.Aquinox Pharma - ‍continues to expect that its cash-on-hand will carry it beyond top-line data from leadership 301 trial and at least to mid-2019.Aquinox Pharmaceuticals Inc - qtrly ‍net loss per common stock $0.50​.Aquinox Pharmaceuticals - ‍cash, cash equivalents, short-term, long-term investments totaled $119.7 million as of Sept 30 versus 153.1 million as of Dec 31, 2016​.  Full Article

Aquinox Pharmaceuticals qtrly loss per share $0.59
Tuesday, 8 Aug 2017 08:05am EDT 

Aug 8 (Reuters) - Aquinox Pharmaceuticals Inc :Aquinox Pharmaceuticals announces second quarter 2017 financial results.Qtrly loss per share $0.59.Aquinox Pharmaceuticals - ‍continues to expect that its cash-on-hand will carry it beyond top-line data from leadership 301 trial and into 2019​.Q2 earnings per share view $-0.51 -- Thomson Reuters I/B/E/S.Aquinox Pharmaceuticals - ‍announcing its plans to initiate a proof-of-concept phase 2 trial with rosiptor (AQX-1125) in patients with CP/CPPS​.  Full Article

Aquinox Pharmaceuticals Qtrly loss per share $0.36
Tuesday, 9 May 2017 09:15am EDT 

May 9 (Reuters) - Aquinox Pharmaceuticals Inc ::Aquinox Pharmaceuticals announces first quarter 2017 financial results.Qtrly loss per share $0.36.Aquinox Pharmaceuticals Inc - top line data from leadership 301 trial is anticipated in 2018.Aquinox Pharmaceuticals Inc - continue to expect that our cash-on-hand will carry us beyond top-line data from 301 trial and into 2019.  Full Article

Aquinox Pharmaceuticals says Q1 loss per share $0.36
Tuesday, 9 May 2017 06:25am EDT 

May 9 (Reuters) - Aquinox Pharmaceuticals Inc : :Says Q1 net loss $8.3 million.Aquinox Pharmaceuticals says plans to provide guidance on top line data availability from leadership 301 trial in early August.Says top line data from leadership 301 trial is anticipated in 2018.Q1 loss per share $0.36.  Full Article

Aquinox Pharma announces year end 2016 financial results
Thursday, 9 Mar 2017 04:06pm EST 

Aquinox Pharmaceuticals Inc : Aquinox Pharmaceuticals announces year end 2016 financial results .Aquinox Pharmaceuticals Inc says net loss for year ended december 31, 2016 was $37.0 million compared to a net loss of $21.9 million for 2015.  Full Article

T. Rowe Price Associates Inc reports 14.4 pct passive stake in Aquinox Pharmaceuticals
Tuesday, 11 Oct 2016 10:10am EDT 

T. Rowe Price Associates Inc:T. Rowe Price Associates Inc reports 14.4 percent passive stake in Aquinox Pharmaceuticals Inc as of sept. 30 - SEC filing.  Full Article

Aquinox Pharmaceuticals Inc - qtrly loss per share $0.63
Thursday, 4 Aug 2016 04:15pm EDT 

Aquinox Pharmaceuticals Inc : Aquinox Pharmaceuticals announces second quarter 2016 financial results . Qtrly loss per share $0.63 .Q2 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.  Full Article

Aquinox Pharmaceuticals reports Q1 net loss per common stock of $0.39
Tuesday, 10 May 2016 09:05am EDT 

Aquinox Pharmaceuticals Inc : Aquinox pharmaceuticals inc qtrly net loss per common stock 0.39 . Q1 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S .Aquinox pharmaceuticals announces first quarter 2016 financial results.  Full Article

BRIEF-‍Aquinox Statement On Fda Advisory Committee Meeting To Discuss Interstitial Cystitis/Bladder Pain Syndrome​

* ‍AQUINOX STATEMENT ON FDA ADVISORY COMMITTEE MEETING TO DISCUSS INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME​